THE SENATE THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII

S.B. NO.446

_

JAN 2 0 2023

A BILL FOR AN ACT

RELATING TO PRESCRIPTION DIGITAL THERAPEUTICS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1	. (a) The department of health shall conduct a
2	study to deter	mine the feasibility of implementing a pilot
3	program to int	egrate innovative, evidence-based prescription
4	digital therap	eutics approved by the federal Food and Drug
5	Administration	in outpatient treatment programs for persons with
6	substance use	disorder or opioid use disorder within the State.
7	The study shal	l consider:
8	(1) Any	potential short-term and long-term financial
9	effe	cts on the State for the pilot program, which
10	shal	l include:
11	(A)	The demographics and needs of persons with
12		substance use disorder or opioid use disorder
13		within the State;
14	(B)	The costs and benefits of different approved
15		prescription digital therapeutic products in the
16		State, including any security and privacy
17		considerations; and



1

S.B. NO.446

1		(C) How various governmental entities can best help
2		provide medical assistance coverage of the
3		approved prescription digital therapeutic
4		products for the treatment of substance use
5		disorders and opioid use disorders, including any
6		immediate and ongoing availability of federal
7		funds;
8	(2)	Any oversight and regulatory requirements necessary to
9		implement the pilot program, including any potential
10		hurdles and strategies to address the potential
11		hurdles;
12	(3)	Any effect of the pilot program on relevant existing
13		health care providers and health care organizations,
14		programs, and agencies;
15	(4)	Any other beneficial alternative options;
16	(5)	Which agency or agencies are best equipped to
17		administer the pilot program, including how the pilot
18		program should be structured;
19	(6)	Which facility or facilities in the State are best
20		suited to implement the pilot program;



Page 3

S.B. NO. 446

1 Which approved prescription digital therapeutic (7) products best fit the needs of persons with substance 2 3 use disorder or opioid use disorder in the State; 4 (8) How to evaluate the outcomes of the pilot program, 5 including preferred frameworks to gauge the impact of the approved prescription digital therapeutic 6 7 products, especially when used in conjunction with other treatments and therapies; and 8 Other considerations necessary to help health care 9 (9) 10 decision makers accurately anticipate the impact of 11 approved prescription digital therapeutic products on 12 the overall delivery of health care in the State. 13 The department of health shall submit a report of its (b) 14 findings and recommendations from the study, including any 15 proposed legislation, to the legislature no later than twenty days prior to the convening of the regular session of 2024. 16 SECTION 2. This Act shall take effect upon its approval. 17 18

INTRODUCED BY:



S.B. NO.446

Report Title:

Department of Health; Feasibility Study; Pilot Program; Prescription Digital Therapeutics; Outpatient Treatment; Substance Use Disorder; Opioid Use Disorder

Description:

Requires the Department of Health to conduct a study to determine the feasibility of implementing a pilot program to integrate prescription digital therapeutic products approved by the federal Food and Drug Administration in outpatient treatment programs for persons with substance use disorder and persons with opioid use disorder in the State. Requires a report to the Legislature.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

